Saturday 17 October 2026
Export NIKI’s income statement to Excel — free account
Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
2.03
0.19
−8.56%
Follow NIKI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 1,325.00 | 1,180.00 | 116.00 | 147.00 | 40.00 | 13.60 | 4.60 | 6.90 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 1,585.00 | 3,328.00 | 1,825.00 | 494.00 | 235.00 | 90.00 | 174.90 | 48.00 | |||||
| People | |||||||||||||||
| People | Employees | — | 46 | 41 | 37 | 26 | 26 | 19 | 3 | 1 | 2 | ||||
| Revenue/emp, $m | — | 0.00 | 0.01 | 0.01 | 0.04 | 0.06 | 0.07 | 0.14 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 0 | 1 | 1 | 2 | 1 | 0 | — | — | ||||
| Gross margin, % | — | 0.00 | 17.05 | (48.47) | (11.35) | 5.31 | 6.18 | 2.46 | — | — | |||||
| EBT | — | 0 | (15) | (20) | 5 | (27) | (12) | (4) | (4) | (1) | |||||
| EBT margin, % | — | 0.00 | (3,946.41) | (3,758.76) | 539.79 | (1,758.61) | (889.35) | (1,006.26) | 0.00 | 0.00 | |||||
| Net income | — | 0 | (15) | (20) | 5 | (27) | (12) | (4) | (4) | (1) | |||||
| Depreciation | — | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 1.37 | 1.84 | 2.93 | 4.40 | 3.63 | 0.95 | 0.00 | 0.00 | ||||
| Earnings | — | (0.85) | (53.00) | (64.00) | 20.00 | (71.00) | (27.50) | (6.20) | (7.80) | (1.90) | |||||
| Cash flow | — | 0.00 | (35.96) | (46.13) | (51.16) | (41.83) | (34.52) | (17.09) | (2.18) | (2.50) | |||||
| Capex | — | 0.00 | (21.73) | (3.13) | 2.86 | (0.41) | (0.52) | 0.03 | 0.11 | 0.00 | |||||
| Free cash flow | — | 0.00 | (57.68) | (49.26) | (48.30) | (42.24) | (35.04) | (17.06) | (2.07) | (2.50) | |||||
| Book value | — | 10.04 | 117.33 | 51.20 | 122.52 | 49.97 | 21.95 | 34.03 | 21.60 | 18.70 | |||||
| Shares, m | — | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 254.64 | 0.00 | 0.00 | 0.00 | — | — | ||||
| P/S | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| EV/Sales | — | — | 0.00 | 0.00 | (20.27) | (3.37) | 0.49 | 0.55 | — | — | |||||
| EV/FCF | — | — | 0.00 | 0.00 | 0.56 | 0.19 | (0.03) | (0.04) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (10) | (13) | (16) | (15) | (12) | (8) | (1) | (2) | ||||
| Capex | — | 0 | (6) | (1) | 1 | 0 | 0 | 0 | 0 | — | |||||
| Free cash flow | — | 0 | (16) | (14) | (15) | (15) | (13) | (8) | (1) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 19 | 17 | 5 | 30 | 8 | (5) | 0 | (3) | (1) | ||||
| Total debt | — | 0 | 10 | 7 | 3 | 0 | 7 | 3 | 3 | 3 | |||||
| Net debt | — | (19) | (17) | 0 | (29) | (8) | 1 | 1 | 2 | 0 | |||||
| Shareholders’ equity | — | 30 | 33 | 15 | 38 | 18 | 8 | 15 | 12 | 14 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (6.65) | (38.71) | (54.14) | 18.51 | (75.75) | (45.82) | (13.61) | (23.21) | (7.83) | ||||
| ROIC | — | 0.00 | (40.96) | (76.81) | (143.66) | (129.97) | (118.55) | (40.78) | (17.42) | (8.29) | |||||
| ROE | — | (8.04) | (47.10) | (78.52) | 23.81 | (90.01) | (77.35) | (24.33) | (31.43) | (10.68) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Jan 0001 · fundamentals updated 5 Oct 2026
Charts ten years each
Niki BioSolutions, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XCUR Exicure, Inc. | $7.3M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $7.0M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.0M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| NIKI Niki BioSolutions, Inc. | $6.9M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | |
| AIM AIM ImmunoTech Inc. | $6.8M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.7M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | Compare |
| ACXP Acurx Pharmaceuticals, Inc. | $6.5M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $6.9M | — | — | −39.66% | — | +13.34% | 76.74% | 0.00% |
Niki BioSolutions, Inc. (NIKI) key facts
- Concern: Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
- Niki BioSolutions, Inc. (NIKI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NIKI traded at $2.03, a market capitalization of $6.9 million.
- Return on equity was −10.7% and debt-to-equity 0.25.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −5.03 (distress zone) for fiscal 2023.